These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Changes in androgen receptor nongenotropic signaling correlate with transition of LNCaP cells to androgen independence. Unni E; Sun S; Nan B; McPhaul MJ; Cheskis B; Mancini MA; Marcelli M Cancer Res; 2004 Oct; 64(19):7156-68. PubMed ID: 15466214 [TBL] [Abstract][Full Text] [Related]
3. 5alpha-androstane-3alpha,17beta-diol supports human prostate cancer cell survival and proliferation through androgen receptor-independent signaling pathways: implication of androgen-independent prostate cancer progression. Yang Q; Titus MA; Fung KM; Lin HK J Cell Biochem; 2008 Aug; 104(5):1612-24. PubMed ID: 18320593 [TBL] [Abstract][Full Text] [Related]
4. A novel synthetic androgen receptor ligand, S42, works as a selective androgen receptor modulator and possesses metabolic effects with little impact on the prostate. Min L; Yanase T; Tanaka T; Fan W; Nomura M; Kawate H; Okabe T; Takayanagi R; Nawata H Endocrinology; 2009 Dec; 150(12):5606-16. PubMed ID: 19854864 [TBL] [Abstract][Full Text] [Related]
5. Signal transduction pathways in androgen-dependent and -independent prostate cancer cell proliferation. Ghosh PM; Malik SN; Bedolla RG; Wang Y; Mikhailova M; Prihoda TJ; Troyer DA; Kreisberg JI Endocr Relat Cancer; 2005 Mar; 12(1):119-34. PubMed ID: 15788644 [TBL] [Abstract][Full Text] [Related]
6. Interruption of nuclear factor kappaB signaling by the androgen receptor facilitates 12-O-tetradecanoylphorbolacetate-induced apoptosis in androgen-sensitive prostate cancer LNCaP cells. Altuwaijri S; Lin HK; Chuang KH; Lin WJ; Yeh S; Hanchett LA; Rahman MM; Kang HY; Tsai MY; Zhang Y; Yang L; Chang C Cancer Res; 2003 Nov; 63(21):7106-12. PubMed ID: 14612503 [TBL] [Abstract][Full Text] [Related]
7. Androgens up-regulate the insulin-like growth factor-I receptor in prostate cancer cells. Pandini G; Mineo R; Frasca F; Roberts CT; Marcelli M; Vigneri R; Belfiore A Cancer Res; 2005 Mar; 65(5):1849-57. PubMed ID: 15753383 [TBL] [Abstract][Full Text] [Related]
8. Dihydrotestosterone interacts with EGFR/MAPK signalling and modulates EGFR levels in androgen receptor-positive LNCaP prostate cancer cells. Mukherjee B; Mayer D Int J Oncol; 2008 Sep; 33(3):623-9. PubMed ID: 18695894 [TBL] [Abstract][Full Text] [Related]
9. TGF-beta signaling and androgen receptor status determine apoptotic cross-talk in human prostate cancer cells. Zhu ML; Partin JV; Bruckheimer EM; Strup SE; Kyprianou N Prostate; 2008 Feb; 68(3):287-95. PubMed ID: 18163430 [TBL] [Abstract][Full Text] [Related]
10. PC-SPES: Molecular mechanism to induce apoptosis and down-regulate expression of PSA in LNCaP human prostate cancer cells. Ikezoe T; Chen SS; Yang Y; Heber D; Taguchi H; Koeffler HP Int J Oncol; 2003 Nov; 23(5):1461-70. PubMed ID: 14532991 [TBL] [Abstract][Full Text] [Related]
11. Zyflamend inhibits the expression and function of androgen receptor and acts synergistically with bicalutimide to inhibit prostate cancer cell growth. Yan J; Xie B; Capodice JL; Katz AE Prostate; 2012 Feb; 72(3):244-52. PubMed ID: 21656835 [TBL] [Abstract][Full Text] [Related]
12. Neoisoliquiritin exerts tumor suppressive effects on prostate cancer by repressing androgen receptor activity. Chen C; Shao R; Li B; Zhai Y; Wang T; Li X; Miao L; Huang J; Liu R; Liu E; Zhu Y; Gao X; Zhang H; Wang Y Phytomedicine; 2021 May; 85():153514. PubMed ID: 33676083 [TBL] [Abstract][Full Text] [Related]
13. 6-(3,4-Dihydro-1H-isoquinoline-2-yl)-N-(6-methoxypyridine-2-yl) nicotinamide-26 (DIMN-26) decreases cell proliferation by induction of apoptosis and downregulation of androgen receptor signaling in human prostate cancer cells. Choi HE; Shin JS; Leem DG; Kim SD; Cho WJ; Lee KT Chem Biol Interact; 2016 Dec; 260():196-207. PubMed ID: 27720946 [TBL] [Abstract][Full Text] [Related]
14. Antiandrogenic effects of novel androgen synthesis inhibitors on hormone-dependent prostate cancer. Long BJ; Grigoryev DN; Nnane IP; Liu Y; Ling YZ; Brodie AM Cancer Res; 2000 Dec; 60(23):6630-40. PubMed ID: 11118046 [TBL] [Abstract][Full Text] [Related]
15. A cross-talk between the androgen receptor and the epidermal growth factor receptor leads to p38MAPK-dependent activation of mTOR and cyclinD1 expression in prostate and lung cancer cells. Recchia AG; Musti AM; Lanzino M; Panno ML; Turano E; Zumpano R; Belfiore A; Andò S; Maggiolini M Int J Biochem Cell Biol; 2009 Mar; 41(3):603-14. PubMed ID: 18692155 [TBL] [Abstract][Full Text] [Related]
16. Identification of an anabolic selective androgen receptor modulator that actively induces death of androgen-independent prostate cancer cells. Schmidt A; Meissner RS; Gentile MA; Chisamore MJ; Opas EE; Scafonas A; Cusick TE; Gambone C; Pennypacker B; Hodor P; Perkins JJ; Bai C; Ferraro D; Bettoun DJ; Wilkinson HA; Alves SE; Flores O; Ray WJ J Steroid Biochem Mol Biol; 2014 Sep; 143():29-39. PubMed ID: 24565564 [TBL] [Abstract][Full Text] [Related]
17. Growth hormone (GH) receptors in prostate cancer: gene expression in human tissues and cell lines and characterization, GH signaling and androgen receptor regulation in LNCaP cells. Weiss-Messer E; Merom O; Adi A; Karry R; Bidosee M; Ber R; Kaploun A; Stein A; Barkey RJ Mol Cell Endocrinol; 2004 May; 220(1-2):109-23. PubMed ID: 15196705 [TBL] [Abstract][Full Text] [Related]
18. Resveratrol inhibits DHT-induced progression of prostate cancer cell line through interfering with the AR and CXCR4 pathway. Jang YG; Go RE; Hwang KA; Choi KC J Steroid Biochem Mol Biol; 2019 Sep; 192():105406. PubMed ID: 31185279 [TBL] [Abstract][Full Text] [Related]
19. Activation of p53 signaling and inhibition of androgen receptor mediate tanshinone IIA induced G1 arrest in LNCaP prostate cancer cells. Won SH; Lee HJ; Jeong SJ; Lü J; Kim SH Phytother Res; 2012 May; 26(5):669-74. PubMed ID: 21997969 [TBL] [Abstract][Full Text] [Related]
20. Capillarisin blocks prostate-specific antigen expression on activation of androgen receptor in prostate carcinoma cells. Tsui KH; Chang YL; Feng TH; Hou CP; Lin YH; Yang PS; Lee BW; Juang HH Prostate; 2018 Mar; 78(4):242-249. PubMed ID: 29164633 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]